Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...

CAR2119’s single-infusion approach offers cost and compliance advantages, though its competitors maintain strong commercial ...

Researchers at the Medical University of Vienna have uncovered how a little-studied protein, TRAT1 (T Cell Receptor ...

T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...

Autoimmune rheumatic diseases (ARDs), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic ...

Recent research indicates that the spatial architecture of membrane proteins is crucial for regulating T-cell signaling and activation. 3-5 In the context of CAR T cells, the nanoscale localization ...

Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...

In vivo CD19 CAR T-cell therapy showed promising results in a feasibility study of five patients with refractory systemic ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Early research has identified several antigens that could ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Company’s Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor ...

生命科学Life science2025年10月2日，中国科学院分子细胞科学卓越创新中心许琛琦课题组、中国科学院深圳先进技术研究院合成生物学研究所施小山课题组与上海科技大学王皞鹏课题组合作，在Cell Press细胞出版社旗下期刊Molecular ...